Navigation Links
PDI Reports 2009 Second Quarter Financial Results
Date:8/5/2009

representatives. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2008, and PDI's subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(Tables to follow)

    PDI, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
    (in thousands, except for per share data)

                                 Three Months Ended    Six Months Ended
                                       June 30,           June 30,
                                 ------------------  -------------------
                                    2009     2008      2009      2008
                                 --------- --------  ---------  --------
     Revenue, net                 $16,291  $30,399   $39,822   $62,628
    Cost of services                9,409   26,809    27,969    50,339
                                 --------- --------  ---------  --------
      Gross profit                  6,882    3,590    11,853    12,289

    Compensation expense            5,754    7,177    12,047    13,310
    Other selling, general and
     administrative expenses        4,000    4,313     8,258     8,587
    Facilities realignment          1,810        -     1,810         -
                                 --------- --------  ---------  --------
      Total operating expenses     11,564   11,490    22,115    21,897
       
'/>"/>
SOURCE PDI, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
3. NxStage Reports Second Quarter 2009 Financial Results
4. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
5. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
6. CuraGen Reports Second Quarter 2009 Financial Results
7. ERT Reports Second Quarter 2009 Results
8. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
9. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
10. Caliper Life Sciences Reports Second Quarter 2009 Results
11. Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/28/2014)... NY (PRWEB) August 28, 2014 Whitehouse ... its long term partnership with PTI Inspection Systems ... clients with state of the art leak testing method ... the art instruments currently available. As part of this ... High Voltage Leak Detection Instrument developed and ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a biopharmaceutical ... data from its ICH compliant Phase II equivalent,multi-center ... allergic,rhinitis. MRX-4 was given as an intranasal spray ... was conducted in allergic,rhinitis patients outside of the ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 13,2008, at ... and operating,performance for its first fiscal quarter ended ... product development and marketing activities., Corgenix invites ...
... ... flavor enhancer may be used in beverages, foods and oral care ... to reduce the need for sucralose, SAN DIEGO, CA AND ... a leading company,focused on using proprietary technologies to discover and develop ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5
(Date:8/27/2014)... may not be getting effective doses of the HIV ... The initial dosing studies, completed before the drug was ... a protein that is key to removing maraviroc from ... maximum levels of the protein including nearly half ... their bodies compared to those who lack the protein ...
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... listen carefully to someone, the first thing we do ... stop moving altogether. This strategy helps us hear better ... , This interplay between movement and hearing also has ... has long suggested that the brain,s motor cortex, which ... rise to our conscious perception of sound. , A ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... Research Hospital have discovered that a certain differentiated cell ... it requires the constant expression of a gene called ... that Prox1 acts as a two-way switch whose inactivity ... called a lymphatic endothelial cell (LEC). In the absence ...
... and then presented with a chemoattractant signal like cAMP, individual ... a migrating stream. This is the first step in a ... organism. Kriebel et al. show how this streaming response is ... issue of the Journal of Cell Biology ( ...
... deformity known as pectus excavatum corrected report improved body ... published December in the journal Pediatrics . ... telephone interviews of more than 200 patients between the ... surgery. Researchers interviewed parents as well. The ...
Cached Biology News:Reprogrammable cell type depends on a single gene to keep its identity 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3
Request Info...
NATIVE RAT OSTEOCALCIN...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: